Abstract
Cancer of the exocrine pancreas represents the fifth leading cause of cancer death in the Western population with an average survival after diagnosis of 3 to 6 months and a five-year survival rate under 5%. Our understanding of the molecular carcinogenesis has improved in the last few years due to the development of novel molecular biological techniques. Pancreatic cancer is a multi-stage process resulting from the accumulation of genetic changes in the somatic DNA of normal cells. In this article we describe major genetic alterations of pancreatic cancer, mutations in the proto-oncogene \textit{K-RAS} and the tumor suppressors \textit{INK4A}, \textit{TP53} and \textit{DPC4}/\textit{SMAD4}. The accumulation of these genetic changes leads to a profound disturbance in cell cycle regulation and continuous growth. The knowledge of the underlying molecular mechanisms will offer new therapeutic and diagnostic options and hopefully improve the outcome of this aggressive disease.

Review
Cancer of the exocrine pancreas represents the fifth leading cause of cancer death in the Western population with a five-year survival rate under 5% [1]. Because of the few treatment options, understanding of the molecular pathology is prerequisite to identify potential molecular targets for drug therapy.

The PanIN (Pancreatic intraepithelial neoplasia) classification describes various changes in the pancreatic duct system distinguishing three PanIN grades (PanIN 1 – PanIN 3) according to the degree of structural dysplasia and cytological atypia present in the lesions [2]. Microdissection techniques revealed genetic alteration in cancer-causing genes in the putative premalignant lesions similar to pancreatic carcinomas (see table 1). The combination of morphological and genetic observations leads to a tumor progression model for pancreatic carcinoma, comparable to the adenoma-carcinoma sequence in colorectal carcinomas [3]. The sequential acquisition of mutations in the proto-oncogene \textit{K-RAS} and the tumor suppressors \textit{INK4A}, \textit{TP53} and \textit{DPC4}/\textit{SMAD4} leads to a profound disturbance in cell cycle regulation, a hallmark of pancreatic cancer. Mutations in \textit{K-RAS}, \textit{INK4A}, \textit{TP53} and \textit{DPC4}/\textit{SMAD4} are frequent, whereas mutations in the tumor suppressor \textit{BRCA2}, mismatch repair genes and the serine-threonine kinases \textit{AKT2} and \textit{LKB1}/\textit{STK11} are rare genetic events. Table 1 summarizes the reported frequencies of major genetic alterations in the pancreatic tumor progression model.

Genetic alterations with high frequency
Pancreatic cancer has the highest incidence of \textit{RAS} mutations in human tumors identified to date [4]. The mutations of the \textit{K-RAS} gene, \textit{H-RAS} and \textit{N-RAS} are not affected, are generally found in codon 12. Dependent on the used technique the frequencies of codon 12 mutations reported range from 20 to 100% and occur early in the tumor progression model [5,6]. The \textit{RAS} family proteins encode small GTP-binding cytoplasmic proteins that mediate pleiotropic effects including cell proliferation, survival and migration [7]. Mutation of codon 12 in \textit{K-
Table 1: Frequency of major genetic alterations in pancreatic carcinoma.

| Gene      | Reference | Normal | PanIN1A | PanIN1B | PanIN2 | PanIN3 | Carcinoma |
|-----------|-----------|--------|---------|---------|--------|--------|-----------|
| K-RAS     | [6]       | 0%     | 38%     | 44%     | 87%    | ~90%   |
|           | [36]      | 3%     | 30%     | 31%     | 73%    | 100%   |
| INK4a     | [19]      | 0%     | 30%     | 27%     | 55%    | 71%    | 40%       |
|           | [14]      |        |         |         |        |        | 40%       |
| TP53      | [37]      | 0%     |         |         | 12%    | 36%    | 40%       |
|           | [35]      |        |         |         |        |        | 40%       |
|           | [36]      | 0%     | 0%      | 0%      | 9.1%   | 57%    | 47%       |
|           | [9]       | 0%     | 0%      | 0%      | 0%     | 31%    | 55%       |
| DPC4/Smad4| [47]      | 0%     | 0%      | 0%      | 0%     | 33%    | 66%       |

RAS results in a gain of function, because the RAS protein remains trapped in the activated state. Considering RAS transforming potential, tissue and species differences come into question. In general epithelial human cells are not very sensitive to oncogene transformation. In contrast primary murine fibroblasts can be efficiently transformed by mutated RAS in concert with a second oncogene or loss of a tumor suppressor, like p53 or p16INK4a. The sole expression of oncogenic RAS in primary rodent and human cells results in a permanent G1 arrest accompanied by accumulation of p53, p16INK4a and p21CIP1 [8]. This senescence is thought to be a defense mechanism against oncogenic stress. Whether the observed overexpression of p21CIP1, whose frequency parallels that of K-RAS, could explain in part the observation that oncogenic K-RAS mutations are not specific for malignancy, being present in benign diseases of the pancreas and in early clonal lesions. Moreover, the risk of progression to malignancy is low in the absence of co-operating genetic events [11–14]. Despite the high mutation frequency in human pancreatic carcinoma, mice which harbor a latent allele of K-Ras912D capable of spontaneous activation in vivo, develop multiple early onset lung tumors but not pancreatic cancer, further demonstrating the species differences of RAS function [15]. The complexity of RAS function is amplified through recent data suggesting tumor suppressor properties of RAS. Transfection of wildtype RAS into rat fibroblasts inhibits anchorage-independent growth and colony formation, induced by the oncogenic RAS gene [16]. Furthermore – in vivo – Kras2 can inhibit lung carcinogenesis in mice [17]. A tumor suppressor function of K-RAS might also exist in the pancreas. Loss of the wildtype K-RAS allele was observed in some pancreatic carcinoma cell lines with mutation in K-RAS (ASPC1, Capan1 and MiaPaca) and there was underexpression of the mutated allele in comparison to the wildtype allele in two other cell lines (Su8686 and Panc1) [5]. A further species difference affects the signaling pathway utilized by oncogenic RAS. Whereas in rodent cells the Raf/MAPK and the PI3K are thought to mediate many effects of oncogenic Ras, there are hints that in human cells the guanine nucleotide exchange factor Ral is sufficient for Ras transformation [18]. Therefore, the net outcome of RAS activation in a specific setting is not easy to predict and further studies, including primary cultures of epithelial pancreas cells, are needed.

Homozigous deletion of p16INK4a/p14ARF locus is a characteristic genetic alteration observed in 80% – 95% of human pancreatic cancer and usually occurs in later stages of the tumor progression model [19–21]. This locus on chromosome 9q21 encodes the two related tumor suppressor genes INK4a and ARF, whose coding sequence partially overlap. INK4a and ARF are generated by the use of a different first exon and an alternative reading frame in exon 2. Whereas INK4a regulates cell cycle progression as an inhibitor of the cyclin D/CDK4/6 kinase complex, ARF directly interacts with Mdm 2/HDM 2 to block the interaction with p53 by localizing Mdm 2/HDM 2 to the nucleolus and by inhibiting directly Mdm 2/HDM 2’s E3 ubiquitin ligase activity, contributing to p53 activation (figure 1) [22]. Gene deficient mice for p19ARF, the mouse homologue of human p14ARF, strongly suggest that Arf is the major tumor suppressor in mice [23,24]. The specific mutation of the Ink4a gene in mice also establishes p16INK4a as a tumor suppressor in mice [25,26]. Germline mutations in the exon 1a of INK4a are associated with the Familial Atypical Mole-Malignant Melanoma syndrome, implicating INK4a in human tumor susceptibility [27]. This mutation also predispose to pancreatic cancer, but in contrast to very high penetrance and early onset of
Figure 1
The INK4a/ARF locus. The two products of the INK4a/ARF locus encode for p16\textsuperscript{INK4a} and p14\textsuperscript{ARF} (p19\textsuperscript{Arf} in mice). p16\textsuperscript{INK4a} indirectly regulates RB function and p14\textsuperscript{ARF} indirectly stabilizes p53.
melanoma, the penetrance of pancreatic cancer is very low and displays latency similar to the sporadic disease [28–30]. In humans INK4a seems to be the more important tumor suppressor for pancreatic cancer development, because germline and sporadic mutations have been identified that target INK4a, but omit ARF [21,31,32]. Mutations that selectively target ARF are rare findings [33]. In sporadic tumors INK4a is inactivated by homozygous deletions and intragenic mutation and in the remaining cases the INK4a gene is turned off through promoter methylation [20,34].

The TP53 tumor suppressor gene is mutated, especially by missense mutations in sequences coding for the DNA binding domain, in greater than 50% of pancreatic adenocarcinomas. The mutations are often accompanied by loss of the wildtype allele and occur late in the progression model [21,35–39]. The transcription factor p53 regulates an essential growth checkpoint that both protects against genomic rearrangement or the accumulation of mutations, and suppresses cellular transformation caused by oncogene activation or the loss of tumor suppressor pathways. p53 is stabilized and activated by extracellular stress including γ irradiation and intracellular stress such as deregulation of cellular oncogenes. Once activated, p53 can induce cell cycle arrest or apoptosis [40]. Loss of p53 is associated with aneuploidy, an outstanding feature of pancreatic cancer, indicating that p53 function maintains genomic stability [41,42]. Germline mutations in TP53 have been described as Li-Fraumeni syndrome, predisposing to several neoplasms, but pancreatic carcinomas are rare findings [43,44]. SMAD4, which was initially named DPC4, deleted in pancreatic carcinoma, was originally identified as a candidate tumor suppressor that is frequently inactivated in pancreatic tumors [45]. The transcription factor SMAD4 is an important regulator of the transforming growth factor β (TGF-β) signaling pathway [46]. Upon receptor activation SMAD proteins get phosphorylated and heterodimerize with Smad4 to transmit upstream signals to the nucleus and transactivate transcription of specific target genes. The SMAD4 gene is deleted or mutated in over 50% of pancreatic cancer, an event occurring late in the tumor progression model [9,47]. The most prominent biological activity of TGF-β is its potent inhibition of cell growth, mediated by a cell cycle G1 arrest, in a wide variety of cells. It is assumed that the growth-inhibitory function of TGF-β is important for SMAD4 tumor suppressor activity. But recent data also suggest TGF-β independent SMAD4 function. Restoration of SMAD4 in human pancreatic carcinoma cells suppressed tumor formation in vivo and did not restore TGF-β sensitivity. Furthermore a decrease in pro-angiogenic VEGF expression and an increase in the angiogenesis inhibitor TSP-1 was observed, so that regulation of an angiogenic switch might contribute to the tumor suppressor function of SMAD4 [48]. Epigenetic inactivation of the TGF-β/SMAD4 pathway occurs in the presence of activated RAS, whereby explaining the reduced selection pressure for LOH at the SMAD4 locus [49]. Recent studies suggest a more aggressive behavior of SMAD4 negative pancreatic cancers [50,51].

**Genetic alterations with low frequency**

BRCA2 on chromosome 13q encodes for a protein that is needed for the maintenance of genomic stability by regulating DNA repair processes. Normal cells, deficient for BRCA2, accumulate lethal chromosomal aberrations [52]. Inherited BRCA2 mutation predispose to early onset familiar breast and ovarian cancer [53]. Albeit with lower penetrance and equal age of onset, inherited BRCA2 mutations also increase the risk for pancreatic cancer [54,55]. In sporadic pancreatic cancer BRCA2 is inactivated in 7 to 10% and lately the biallelic inactivation in a high-grade duct lesion was demonstrated, so that it is assumed that BRCA2 mutation occur late in the neoplastic progression in the pancreas [56].

The autosomal dominant inherited Peutz-Jeghers syndrome, caused by mutation of the serine-threonine kinase LKB1/STK11 that maps to chromosom 19p13, is associated with an increased incidence of pancreatic carcinoma [57–60]. The signaling pathway of LKB1/STK1 is so far unknown, but this gene was shown to be inactivated in 5% of sporadic pancreatic cancer, suggesting a possible role in tumor suppression [61,62].

The serine-tenoneine kinase AKT2 is a candidate oncogene for human pancreatic cancer and was found to be amplified and overexpressed in pancreatic adenocarcinoma and cell lines in up to 20% [63–65]. AKT2 is a downstream effector of the PI3 kinase and can be activated by epidermal growth factor, platelet-derived growth factor and basic fibroblast growth factor, all known to be overexpressed in pancreatic carcinoma [66,67]. Recently AKT1 signaling was linked to enforced insulin-like growth factor I receptor expression, promoting invasiveness of pancreatic cancer cells [68].

Autosomal dominant inherited Lynch syndrome is characterized by an increased risk of developing colorectal, endometrial, ovarian and breast cancers, transitional carcinoma of the ureter and renal pelvis [69]. Mutations in the DNA mismatch repair genes, including hMLH1, hMSH2 and hMSH6, cause this syndrome. Pancreatic cancer is included in the tumor spectrum, however, it seems to be a rare finding [70,71]. Pancreatic cancers occurring in context of the Lynch syndrome are different compared to sporadic pancreatic carcinomas in terms of the superior clinical course, histopathology and distinct molecular genetic profiles, including retention of wildtyp RAS [72–74].
Furthermore, microsatellite instability is unlikely to participate in the oncogenesis of spontaneous pancreatic cancer [75–77].

Conclusion
Molecular investigations of pancreatic cancer are complicated by the restricted accessibility of the organ for biopsies. The findings in molecular research on pancreatic carcinoma of the last years is now integrated in a pancreatic tumor progression model, with genetically, epigenetically and morphologically defined precursor lesions. Pancreatic cancer is a genetic disease, but the transition between cancer and non-cancer is not regulated by a simple switch activated by a single gene. In fact, multiple mutations must accumulate in a single cell, including overexpression of receptor-ligand systems, oncogene activation and loss of tumor suppressor genes, to develop pancreatic carcinoma. But where are the diverse genetic alterations, whose number is increasing, integrated? Deregulated cell cycle is the hallmark of many human tumors, including pancreatic carcinoma, and therefore the cell cycle could be placed into the center of pancreatic oncogenesis. As figure 2 illustrates, each of the major genetic alteration mentioned above is involved in cell cycle regulation and leads together to the acceleration of the cell cycle progression and continuous growth.

Further analysis of the underlying molecular mechanism will offer new diagnostic and therapeutic options and, hopefully improve the outcome of this dismal disease in the future.

References
1. Jemal A, Thomas A, Murray T and Thun M Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47
2. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G and Longnecker DS Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001, 25:579-86
3. Hruban RH, Wilentz RE and Kern SE Genetic progression in the pancreatic ducts. Am J Pathol 2000, 156:1821-5
4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-54
5. Caldas C and Kern SE K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995, 18:1-6
CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995, 10:351-3

28. Goldstein AM, Fraser D, Bishop JC, Hussey DJ, Huussajian C, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopolni NC and Clark WH Jr Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4A mutations. N Engl J Med 1995, 333:970-4

29. Whelan AJ, Bartosh D and Goodfellow Pj Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2A tumor-suppressor gene. N Engl J Med 1995, 333:975-7

30. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClelan J and Lynch JF Familial pancreatic cancer: clinicopathologic features of 18 nuclear families. Am J Gastroenterol 1990, 85:54-60

31. Liu L, Dillworth D, Gao L, Monzon J, Summers A, Lassam N and Hogg D Mutation of the CDKN2A S’ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999, 21:128-32

32. Spandidos DA, Frame M and Wilkie NM Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer 2000, 27:358-61

33. Randerson-Moor JA, Harland M, Williams S, D Cutbolt-Hevens, Sheridan E, Aveyard J, Sibert K, Whitaker L, Knowles M and Bishop JN A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001, 10:55-62

34. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabiniband SK, Moskaluk CA, Hahn SA, Schafer-Waldhoff I and Schmieg W Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-30

35. Boschman CR, Stryker S, Reddy JK and Rao MS Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994, 145:1291-5

36. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW and Nieberg RK Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomaous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 1995, 26:123-9

37. Di Giuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, Cameron JL and Offerhaus GJ Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994, 101:684-8

38. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ and Kern SE p53 mutations in pancreatic cancer and evidence of common involvement of homopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-33

39. Bartson CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Kloppe G, Theis B, Russell RC, Neoptolemos J and RC Williamson Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991, 64:1076-82

40. Levine AJ p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-31

41. Harada T, Okita K, Shiraishi K, Kusano N, Kondoh S and Sasaki K Interradialgeron cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res 2002, 62:835-9

42. Gorovina L, Hoglund M, Andreu-Sandberg A, Dawiskiba S, Jin Y, Mitelman F and Johannson B Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 1998, 23:81-99

43. Sturgill LC, Stine M and Norsted TL Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987, 79:1213-20

44. Li FP, Fraumeni JF Jr, Mulhivill JJ, Blattner WA, Dreyfus MG, Tucker MJ and Miller RK A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-62

45. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ and Hruban RH DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-3

46. Massagué J, Blain SW and Lo RS TGFBeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309

47. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE and Hruban RH Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: evidence that
Molecular Cancer 2003, 2  
http://www.molecular-cancer.com/content/2/1/15

DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-6

48. Lowrance-Whitehead I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klei-Na Scory S, Lutgen J, Kloppe G, Graeven U and C Eilers-MicuSmad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A 2000, 97:9624-9

49. Kretzschmar M, Moody J, Timokhina I and Massague J A mechanism of repression of TGFBeta/ Smad signaling by oncogenic Ras. Genes Dev 1999, 13:804-16

50. Tascilar M, Skinner HG, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL and Kern SE The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001, 7:4115-21

51. Blankin AV, Morey AL, Lee CS, Kembitsch M, Sauer H, Koch HD, Head DR, Hugh TB, Sutherland RL and Henshall SM DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma. J Clin Oncol 2002, 20:4531-42

52. Westerman AM, Entius MM, Goggins M and Yeo CJ Amplification of AKT2 in human pancreatic cancer. Cancer 2000, 96:2268-75

53. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumb C, Seal S, Barfoot R, Collins N and Bignell G AKT2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-40

54. Ozcelik H, Schneckler B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G and Andrusil I L. Germline Mutations in the AKT2 Locus in Human Pancreatic Cancer. Am J Hum Genet 2001, 69:1139-44

55. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Goodman SN, Petersen GM, Jackson CE, Lynch HT and Hruban RH Germline Mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-4

56. Goggins M, Hruban RH and Kern SE BRCAl and BRCAl2. Cell 2002, 108:171-82

57. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumb C, Seal S, Barfoot R, Collins N and Bignell G AKT2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-40

58. Westerman AM, Entius MM, Goggins M and Yeo CJ Amplification of AKT2 in human pancreatic cancer. Cancer 2000, 96:2268-75

59. Giardiello FM, Brensinger JD, Tsichlis PN, Kaplan DR and Goggins M, Hruban RH and Kern SE BRCAl and BRCAl2. Cell 2002, 108:171-82

60. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Goodman SN, Petersen GM, Jackson CE, Lynch HT and Hruban RH Germline Mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-4

61. Goggins M, Hruban RH and Kern SE BRCAl and BRCAl2. Cell 2002, 108:171-82

62. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumb C, Seal S, Barfoot R, Collins N and Bignell G AKT2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-40

63. Westerman AM, Entius MM, Goggins M and Yeo CJ Amplification of AKT2 in human pancreatic cancer. Cancer 2000, 96:2268-75

64. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumb C, Seal S, Barfoot R, Collins N and Bignell G AKT2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-40

65. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Goodman SN, Petersen GM, Jackson CE, Lynch HT and Hruban RH Germline Mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-4

66. Goggins M, Hruban RH and Kern SE BRCAl and BRCAl2. Cell 2002, 108:171-82

67. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumb C, Seal S, Barfoot R, Collins N and Bignell G AKT2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-40

68. Goggins M, Hruban RH and Kern SE BRCAl and BRCAl2. Cell 2002, 108:171-82

Publish with BioMed Central and every scientist can read your work free of charge

BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime. Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp